Auditorybrainstem response (ABR) testing isless sensitive in detecting smallvestibular schwannomas than mediumsize tumors. Magnetic resonance imaging (MRI) is more sensitive than ABR alone for small and large tumors, but it carries with it increased cost and issues of unavailability and patient discomfort. We conducted a prospective pilot studyof7 patientswith untreatedMRI-proven, unilateral vestibular schwan noma to determineifwe could increase the sensitivity of ABR testing in detecting small tumors. Our method involved the use"of a new ABR index that is based on threshold differences. All patients underwent pure-tone audiometry followed by a determination of behavioral threshold and neurodiagnostu: threshold ABR in the normal em; which was used as a control, and in the diseased ear. Analysis of results revealed that all 7 patients had an abnormalABR threshold difference, and 5 patients displayed abnormal traditional ABR indices. The mean difference between the ABR and behavioral click thresholds was41.4 dB in the diseased ears (with the ABR threshold beinghigher than the click threshold) and 15.8 dB in the normal ears. None of the control ears had a threshold difference >30 dB.
Introduction
The use of auditory brainstem response (ABR) testing in the screening of retrocochlear pathology such as vestibular schwannomas is widespread. Since ABR testing was first described by Selters and Brackmann in 1977,1 multiple studies':' have shown that its sensitivity exceeds 90%, thus establishing it as the most sensitive audiologic test for the detection of vestibular schwannomas, However, within the past decade, magnetic resonance imaging (MRI) has emerged as the gold standard for the diagnosis and monitoring of vestibular schwannomas. MRI is capable of detecting vestibular schwannomas of any size, while ABR testing tends to be less sensitive for smaller lesions. For example, Schmidt et al reported that ABR testing was only 58% sensitive for detecting lesions 1 cm or smaller that were readily detected by MRI.5The usefulness of ABR testing is also limited by compromised audiologic function, which is typically seen in the setting of retrocochlear pathology. While MRI is more sensitive than ABR alone, it is not always readily available and it adds to treatment costs." Moreover, patient discomfort can be an issue. Finally, MRI is con traindicated in many patien ts because 0 f implan ts or other types ofmetal in the body. Computed tomography (CT) is an option, but it is less sensitive than MRI and it may also miss small lesions.
While ABR testing is a good screening tool in terms of availability, cost, and ease of administration, it would be even better if it were more sensitive in detecting smaller lesions. Detection of these lesions at a smaller size may result in earlier treatment and improved preservation of hearing and facial nerve function .' One advance in ABR technology, the stackedABR,has been shown to improve sensitivity in diagnosing vestibular schwannomas, but this option is more costly and time-consuming than traditional ABR testing.v"
Diagnostic indices for the detection of vestibular schwannomas have been documented by many different authors. These indices are highly dependent on the Medication delivered where it's needed. Nasal symptoms get the message. Introducing 
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Patients and methods
This prospective pilot study involved patients with untreated vestibular schwannomas.After obtaining institutional review board approval, we recruited patients who met our eligibility criteria, and we obtained informed consent. The primary inclusion criterion was the presence of an untreated unilateral vestibular schwannoma, regardless ofsize,that could be monitored both clinically and radiographically (MRI with gadolinium contrast) in our neurotology clinic. Patients with a PTA >60 dB in the diseased ear and those with bilateral vestibular schwannomas were excluded from the study.
During the enrollment period (-18 mo), 40 patients with unilateral vestibular schwannomas presented to our clinic. Of these, 33 were excluded on the basis of a PTA >60 dB, previous treatment, or an unwillingness to participate. The charts of the remaining 7 patients were reviewed for demographic information and for information on the site and size of the vestibular schwannoma. Recent MRIs (~1 yr old) were also reviewed.
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All testing was completed in a sound-treated room or quiet listening environment to reduce ambient noise levels.All patients underwent a full audiometric evaluation using conventional clinical procedures. Thresholds for the octave frequencies from 250 to 8,000 Hz were established with a calibrated GSI 61 audiometer. Patients with air-conduction thresholds > 15 dB also underwent bone-conduction testing to rule out conductive involvement. In addition, speech reception thresholds and word recognition scores were also obtained.
TheABR test was recorded with the Intelligent Biologic Master System (Intelligent Hearing Systems; Miami) using traditional montage and recording techniques. Electrodes were placed on the high forehead and at each mastoid. Impedances were maintained at <5 kOhm and balanced across the electrode array. Expanding on the previouslydescribed threshold comparison described by Marangos et al,12 we obtained a behavioral click-stimulus threshold. The click stimulus, which involves a wide band of frequencies (2,000 to 4,000 Hz), was presented at 90 dB and decreased progressively in 1O-dBincrements and increased in 5-dB steps (modified Hughson-Westlake procedure) until a threshold was established for each ear. An evoked potential threshold was then obtained and compared with the behavioral threshold, and the difference between the two was calculated. Waveform analysis was restricted to waves I, III, and V at 90 dB. The ABR indices were then recorded; they included the wave I-V interval, the ILD, and the absolute latency of waveV. Our institutional values indicating retrocochlear pathology relative to these indices are~4.4 msec for the I-V interval.zu.d msecforthe ILD,and~6.2 msec for the absolute latency ofV. The total amount of testing time for each patient ranged between 15 and 30 minutes.
Results
The 7 patients in our studygroup were aged 49 to 70 years (mean: 59) (table). Five of the patients had at least one abnormal index. (The number ofpatients abnormal for each index is depicted in figure 1.) In 3 of the 7 patients (patients 4, 6, and 7), we were unable to detect a wave I, and therefore a wave I-V interval could not be calculated. This was considered an abnormal finding .All 3 of these patients had at least one other abnormal index. In 1 of those 3 patients (patient 7), we were unable to obtain a reliable waveform on the normal side, and therefore the ILD could not be calculated; this patient had a significant sensorineural hearing loss on the normal side, which may have accounted for the difficulty in obtaining normal waveforms. Failure to obtain traditional indices was considered abnormal in this study. There is much debate in the ABR literature regarding the appropriate index parameters used to identify small vestibular schwannomas. Zappia et al used an ILD of 0.2 msec and reported a sensitivity of 89% in diagnosing tumors < 1em." However,Schmidt et al' emphasized the importance of using the Brackmann correction factor' to account for cochlear loss.We use a parameter of ;:::O.4 msec for ILD, realizing that more lenient parameters may increase our ABR sensitivity but may also increase the number of false positives.
With a samp le size of 7 patients, we intended only to document a trend toward abnormal threshold differences in acoustic vestibular schwannoma patients. Testing a larger number of acoustic vestibular schwan-
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Fi gure I. Chart shows the numberof patients with abnormalABR indices.
The behavioral threshold obtained with the ABR clickwas compared with the neurodiagnostic threshold (table) . The mean threshold difference in the diseased ears was 41.4 dB (with the ABR threshold being higher than the click threshold) , and the mean difference in the normal ears was 15.8 dB (figure 2). A comparison with the normal ear could not be performed in patient 7 because,as mentioned,a reliable waveform and threshold could not be obtained. In accordance with the criteria of Marangos et al," we established a 30-dB threshold difference as indicative of retrocochlear pathology. We found that all 7 patients had an abnormal threshold difference, which meant that our test had a sensitivity of 100%in detecting retrocochlear pathology. None of the normal ears had a threshold difference of >30 dB.
Discussion
In this study, we evaluated patients with untreated, MRI-proven uni lateral vestibular schwannomas with the use of a traditional ABR test and a determination of threshold differences for the purpose of increa sing ABRsensitivity. Our goal was not to attempt to replace MRI with ABR. Rather, we advocate the development of a cost-effective yet accurate algorithm for the diagnostic evaluation of patients with asymmetrical auditory symptoms. The application of the threshold difference is completely dependent on the examiner's ability to determine a reliabl e neurodiagnostic thre shold; this is not possible in all patients, but it does hold promise for the development of new indices in vestibular schwannoma detection. The results of ABR testing in patients with significantly diminished auditory function are typically unreliable, and the se patients should be evaluated radiographically if asymmetrical symptoms exist. As reflected in our exclusion crit eria, we attempted to
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